Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

[FOXA1 expression in luminal-type breast cancer].

Tokunaga E, Hisamatsu Y, Maehara Y.

Nihon Rinsho. 2012 Sep;70 Suppl 7:438-42. Japanese. No abstract available.

PMID:
23350438
2.

Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis.

Thorat MA, Marchio C, Morimiya A, Savage K, Nakshatri H, Reis-Filho JS, Badve S.

J Clin Pathol. 2008 Mar;61(3):327-32. Epub 2007 Nov 23.

PMID:
18037662
3.

FOXA1: a promising prognostic marker in breast cancer.

Hu Q, Luo Z, Xu T, Zhang JY, Zhu Y, Chen WX, Zhong SL, Zhao JH, Tang JH.

Asian Pac J Cancer Prev. 2014;15(1):11-6. Review.

4.

FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.

Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4415-21.

5.

FoxA1 as a lineage-specific oncogene in luminal type breast cancer.

Yamaguchi N, Ito E, Azuma S, Honma R, Yanagisawa Y, Nishikawa A, Kawamura M, Imai J, Tatsuta K, Inoue J, Semba K, Watanabe S.

Biochem Biophys Res Commun. 2008 Jan 25;365(4):711-7. Epub 2007 Nov 26.

PMID:
18039470
6.

Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores.

Ademuyiwa FO, Thorat MA, Jain RK, Nakshatri H, Badve S.

Mod Pathol. 2010 Feb;23(2):270-5. doi: 10.1038/modpathol.2009.172. Epub 2009 Nov 27.

7.

FOXA1 is an independent prognostic marker for ER-positive breast cancer.

Mehta RJ, Jain RK, Leung S, Choo J, Nielsen T, Huntsman D, Nakshatri H, Badve S.

Breast Cancer Res Treat. 2012 Feb;131(3):881-90. doi: 10.1007/s10549-011-1482-6. Epub 2011 Apr 19.

PMID:
21503684
8.

FOXA1 as a therapeutic target for breast cancer.

Nakshatri H, Badve S.

Expert Opin Ther Targets. 2007 Apr;11(4):507-14. Review.

PMID:
17373880
9.

Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer.

Hisamatsu Y, Tokunaga E, Yamashita N, Akiyoshi S, Okada S, Nakashima Y, Aishima S, Morita M, Kakeji Y, Maehara Y.

Ann Surg Oncol. 2012 Apr;19(4):1145-52. doi: 10.1245/s10434-011-2094-4. Epub 2011 Oct 8.

PMID:
21984487
10.

[Diagnostic and prognostic significance of FOXA1 expression in molecular subtypes of breast invasive ductal carcinomas].

Liu N, Niu Y, Wang SL, Yu Q, Zhang RJ, Liu TJ.

Zhonghua Yi Xue Za Zhi. 2010 May 25;90(20):1403-7. Chinese.

PMID:
20646630
11.

Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance.

Habashy HO, Powe DG, Rakha EA, Ball G, Paish C, Gee J, Nicholson RI, Ellis IO.

Eur J Cancer. 2008 Jul;44(11):1541-51. doi: 10.1016/j.ejca.2008.04.020. Epub 2008 Jun 4.

PMID:
18538561
12.

Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients.

Ijichi N, Shigekawa T, Ikeda K, Horie-Inoue K, Shimizu C, Saji S, Aogi K, Tsuda H, Osaki A, Saeki T, Inoue S.

Horm Cancer. 2012 Aug;3(4):147-59. doi: 10.1007/s12672-012-0111-0. Epub 2012 Apr 3.

PMID:
22476979
13.

FOXA1 in breast cancer.

Nakshatri H, Badve S.

Expert Rev Mol Med. 2009 Mar 5;11:e8. doi: 10.1017/S1462399409001008. Review.

PMID:
19261198
14.

Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours.

Albergaria A, Paredes J, Sousa B, Milanezi F, Carneiro V, Bastos J, Costa S, Vieira D, Lopes N, Lam EW, Lunet N, Schmitt F.

Breast Cancer Res. 2009;11(3):R40. doi: 10.1186/bcr2327. Epub 2009 Jun 23.

15.

FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer.

Gerhardt J, Montani M, Wild P, Beer M, Huber F, Hermanns T, M√ľntener M, Kristiansen G.

Am J Pathol. 2012 Feb;180(2):848-61. doi: 10.1016/j.ajpath.2011.10.021. Epub 2011 Dec 2.

PMID:
22138582
16.

Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications.

Badve S, Nakshatri H.

J Clin Pathol. 2009 Jan;62(1):6-12. doi: 10.1136/jcp.2008.059899. Epub 2008 Sep 15. Review.

PMID:
18794199
17.

Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer.

Jacquemier J, Charafe-Jauffret E, Monville F, Esterni B, Extra JM, Houvenaeghel G, Xerri L, Bertucci F, Birnbaum D.

Breast Cancer Res. 2009;11(2):R23. doi: 10.1186/bcr2249. Epub 2009 Apr 30.

18.

Histologic markers and long-term prognosis in breast cancer.

Burtness BA.

Cancer J Sci Am. 1997 Jul-Aug;3(4):211-2. No abstract available.

PMID:
9263626
19.

Estrogen induces repression of the breast cancer and salivary gland expression gene in an estrogen receptor alpha-dependent manner.

Bretschneider N, Brand H, Miller N, Lowery AJ, Kerin MJ, Gannon F, Denger S.

Cancer Res. 2008 Jan 1;68(1):106-14. doi: 10.1158/0008-5472.CAN-07-5647.

20.

Up-regulation of the HSP72 by Foxa1 in MCF-7 human breast cancer cell line.

Song L, Xu Z, Zhang C, Qiao X, Huang C.

Biochem Biophys Res Commun. 2009 Aug 14;386(1):30-4. doi: 10.1016/j.bbrc.2009.05.120. Epub 2009 May 30.

PMID:
19486887
Items per page

Supplemental Content

Write to the Help Desk